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Abstract
Background: Poor distribution of some anticancer drugs in solid tumors may limit their anti-tumor activity.
Methods: Here we used immunohistochemistry to quantify the distribution of the therapeutic monoclonal antibodies 
cetuximab and trastuzumab in relation to blood vessels and to regions of hypoxia in human tumor xenografts. The 
antibodies were injected into mice implanted with human epidermoid carcinoma A431 or human breast carcinoma 
MDA-MB-231 transfected with ERBB2 (231-H2N) that express high levels of ErbB1 and ErbB2 respectively, or wild-type 
MDA-MB-231, which expresses intermediate levels of ErbB1 and low levels of ErbB2.
Results: The distribution of cetuximab in A431 xenografts and trastuzumab in 231-H2N xenografts was time and dose 
dependent. At early intervals after injection of 1 mg cetuximab into A431 xenografts, the concentration of cetuximab 
decreased with increasing distance from blood vessels, but became more uniformly distributed at later times; there 
remained however limited distribution and binding in hypoxic regions of tumors. Injection of lower doses of 
cetuximab led to heterogeneous distributions. Similar results were observed with trastuzumab in 231-H2N xenografts. 
In MDA-MB-231 xenografts, which express lower levels of ErbB1, homogeneity of distribution of cetuximab was 
achieved more rapidly.
Conclusions: Cetuximab and trastuzumab distribute slowly, but at higher doses achieve a relatively uniform 
distribution after about 24 hours, most likely due to their long half-lives in the circulation. There remains poor 
distribution within hypoxic regions of tumors.
Background
The ErbB family of receptor kinases is a group of four
trans-membrane proteins (ErbB1 - ErbB4) that share sim-
ilarities in structure and are involved in signaling path-
ways that stimulate cellular proliferation [1]. Ligand
binding induces receptor homo- and hetero-dimeriza-
tion, although no ligand has been identified for ErbB2.
Dimerization of the receptors stimulates their intrinsic
tyrosine kinase activity resulting in receptor autophos-
phorylation [2]. These phosphorylated residues serve as
binding sites for molecules involved in the regulation of
intracellular signaling cascades. Overexpression of ErbB
receptors may occur in a wide range of epithelial cancers,
including those of the breast [3], colon [4], head and neck
[5], kidney [6], lung [7,8], pancreas [9], prostate [10] and
esophagus [11,12] and has been associated with an
aggressive phenotype.
Molecular targeted agents that interact with receptor
tyrosine kinases on tumor cells are used increasingly in
clinical oncology. There are two classes of agents, mono-
clonal antibodies and low-molecular-weight tyrosine
kinase inhibitors. Cetuximab (chimeric mouse/human)
and trastuzumab (humanized) are monoclonal antibodies
that target the extracellular domain of the receptors
ErbB1 [13-16] and ErbB2 [15,17] respectively. Binding of
cetuximab and trastuzumab to ErbB1 and ErbB2 respec-
tively prevents receptor phosphorylation and activation
of the kinase domain, thereby inhibiting cell proliferation
[18-20]. Binding of trastuzumab to its receptor also
reduces shedding of the extracellular domain of ErbB2
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and prevents the production of an active truncated frag-
ment [20-22]. These agents have shown therapeutic activ-
ity against colorectal cancer and breast cancer
respectively and are in wide clinical use [21,22].
Limited penetration of drugs through tumor tissue is an
important and rather neglected cause of clinical resis-
tance to chemotherapy [23-25]. Drug distribution from
blood vessels within tumors depends on diffusion and
and/or convection, and is inhibited by consumption in
proximal cells [23,25-27]; for monoclonal antibodies con-
sumption is due to binding to the receptor target, which
is dependent on antibody dose, number of antigenic tar-
gets per cell, and the affinity of the antibody for its target
[28]. Convection depends on gradients of pressure (both
hydrostatic and osmotic) between the vascular space and
the interstitial space, while diffusion depends on molecu-
lar size, shape and concentration gradients [26,27].
Because monoclonal antibodies are large molecules they
might be expected to have poor distribution from tumor
blood vessels [28]. However drugs with a long half-life in
the circulation may establish a more uniform distribution
in tissues even if penetration of tissue is relatively slow,
whereas drugs with a short half-life may have a non-uni-
form distribution. Here we report a study of the distribu-
tion of the monoclonal antibodies, cetuximab and
trastuzumab, in tumors that express different levels of
their target receptors.
Methods
Drugs and reagents
The monoclonal antibody cetuximab (IMC-C225,
E r b i t u x )  w a s  p r o v i d e d  b y  I m c l o n e  S y s t e m s ,  I n c .  ( N e w
York, NY, USA) as a solution at a concentration of 2 mg/
ml. Trastuzumab (Herceptin) was obtained from the hos-
pital pharmacy at a concentration of 21 mg/ml. The
hypoxia-selective agent EF5 and Cy5-conjugated anti-EF5
antibody [29,30] were kindly provided by Dr. C. Koch,
Philadelphia, PA. Blood vessels in tumor sections were
visualized with a rat anti-mouse CD31 (PECAM-1)
monoclonal antibody that was purchased from BD
Pharmingen (Mississauga, ON, Canada) and the Cy3-
conjugated goat anti-rat IgG secondary antibody was
purchased from Jackson Immuno Research Laboratories,
Inc. (West Grove, PA). Cetuximab and trastuzumab were
recognized in tissue sections with goat anti-human IgG
conjugated with horseradish peroxidase (Biosource,
Montreal, Canada).
Cell lines and tumor models
Experiments were performed utilizing the ErbB1-overex-
pressing human epidermoid carcinoma (A431) and a
human breast adenocarcinoma (MDA-MB-231), using
both wild-type and ERBB2  transfected (231-H2N) cell
lines. A431 and MDA-MB-231 cells were obtained from
the American Type Culture Collection (Manassas, VA,
USA), while MDA-MB-231 cells transfected with ERBB2
(231-H2N) were kindly provided by Dr. J. Medin [31]
(University of Toronto, ON, Canada). All the cell lines
were maintained as monolayers in Dulbecco's Modified
Eagle's Medium (DMEM), supplemented with 10% fetal
calf serum (FCS), at 37°C in a humidified atmosphere of
95% air plus 5% CO2. Tests were performed routinely to
ensure that cells were free of mycoplasma. Tumors were
generated by injection of ~2 × 106 exponentially-growing
cells into the right and left flanks of 6-8 week old female
athymic nude mice, purchased from Harlan Sprague-
Dawley Laboratory Animal Centre (Madison, WI, USA).
Mice were housed five per cage, and sterile tap water and
food were given ad libitum. All procedures were carried
out following approval of the Institutional Animal Care
Committee.
Expression of ErbB1 and ErbB2 receptors in the xeno-
grafts was confirmed by applying cetuximab or trastu-
zumab to sections of tumors ex vivo, followed by their
recognition using anti-human IgG as described below.
Endogenous expression of ErbB1 and ErbB2 were also
confirmed and assessed by diagnostic antibodies from
Zymed (Clone 31G7) and Neomarkers (Clone SP3)
respectively.
Experimental design
Tumor-bearing mice were divided randomly into groups
of 5-6, and treatment with cetuximab or trastuzumab was
initiated when the diameter of tumors was approximately
7-8 mm. One group was selected randomly as the control,
and the other mice received cetuximab or trastuzumab
(0.01 mg to 1.0 mg) as a single intraperitoneal (i.p.) or
intravenous (i.v.) injection. Control mice were given equal
volumes of PBS. Animals were killed at various intervals
after injection of cetuximab or trastuzumab; they
received an i.p. injection of EF5 (0.2 ml of 10 mM EF5) 2
hours before they were killed in order to identify hypoxic
regions of tumors [29,30]. Tumors were removed and
embedded with Tissue-Tek OCT (Optimal Cutting Tem-
perature, Sakura Finetek USA Inc., Torrance, CA). The
tissue boxes were gently immersed in liquid nitrogen, and
then stored at -70°C.
Cryosections were prepared at 10 μm thickness and tri-
ple stained to identify cetuximab or trastuzumab, CD31
and EF5. Horseradish peroxidase (HRP) conjugated to
anti-human IgG was used to recognize the therapeutic
monoclonal antibodies. DAB (3,3'-diaminobenzidine) is a
chromogenic substrate for HRP and it deposits a brown
specific stain in the presence of HRP. Blood vessels in tis-
sue sections were recognized by the expression of CD31
on endothelial cells. Purified rat anti-mouse CD31 mono-
clonal antibody was applied at a concentration of 1:500
and left overnight at 4°C. Primary antibody binding wasLee and Tannock BMC Cancer 2010, 10:255
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disclosed using a Cy3-conjugated goat anti-rat IgG sec-
ondary antibody. Hypoxic regions were recognized by
cyanine-5-conjugated mouse anti-EF5 (1/50) antibody.
Fluorescence microscopy
Images were tiled using an Olympus BX50 upright fluo-
rescent microscope linked to a Photometrics CoolSnap
HQ2 CCD camera, a motorized X-Y stage connected to a
computer preloaded with Media Cybernetics In Vivo and
Image Pro-PLUS software (Media Cybernetics, Silver
Spring, MD) and a stage controller board. Tumor sections
were scanned and tiled under white light and two differ-
ent filters: (i) images of Cy3 fluorescence of CD31 were
visualized using 530 nm to 560 nm excitation and 573 nm
to 647 nm emission filter sets, while (ii) images of the Cy5
fluorescence of EF5 were visualized with 630 nm to 650
nm excitation and 665 nm to 695 nm emission filter sets.
Composite images of cetuximab, CD31, and EF5 or tras-
tuzumab, CD31 and EF5 were generated using Image Pro
PLUS (version 5) and subsequently pseudo-colored. To
investigate the distribution of drug in relation to distance
from the nearest blood vessel or hypoxic region, images
displaying anti-CD31 staining or EF5 staining were con-
verted to black and white binary images: each image was
overlayed with the corresponding field of view displaying
drug intensity, resulting in an 8-bit black and white image
wi t h  b l ood  v e s s e l s  o r  h ypo x i c  r e gi o n s  i d e n t i fi ed  b y  a n
intensity of 255 (white) and drug intensity ranging from
0-254 (gray scale). Areas of interest were selected from
each tissue section and were on average 1600 × 1600 μm
(0.4 μm2/pixel). Areas of necrosis and staining artifact
were excluded.
Distributions of each monoclonal antibody in relation
to distance from the nearest blood vessel and the nearest
region of hypoxia in the tumor section were quantified
utilizing Image Pro software. A minimum signal level just
below threshold was set for each tissue section; this was
based on an average background reading from regions
without staining. The pixel intensity and distance to the
nearest vessel or region of hypoxia for all pixels within the
selected region of interest above threshold were mea-
sured with a customized algorithm. The intensity of
cetuximab or trastuzumab signal was represented as
mean ± SEM for all pixels at a given distance to the near-
est vessel or region of hypoxia and plotted as a function of
that distance.
Results
Expression of ErbB receptors
Ex vivo staining using cetuximab was used to recognize
expression of ErbB1 in A431 and MDA-MB-231 tumor
sections; these tumors express high and intermediate lev-
els of ErbB1 respectively (Fig. 1, upper panels). Similarly,
ex vivo application of trastuzumab indicates low expres-
sion of ErbB2 in wild-type MDA-MB-231 xenografts and
high expression in the ERBB2-transfected 231-H2N
xenografts (Fig. 1, lower panels). In tumors that express
the receptors the staining indicates their distribution on
the cell membrane.
Expression of receptors was fairly uniform in tumors,
except for regions of hypoxia (defined by EF5 staining)
where there was lower expression of ErbB1 and ErbB2.
We also studied receptor expression in tumors of animals
that were treated with the therapeutic antibodies, and
found no effect of treatment on receptor expression.
Time- and dose-dependent distribution of cetuximab
Dose-dependent distribution of cetuximab in A431 xeno-
grafts 24 h after i.p. injection of different doses is shown
in Fig. 2. After injection of 0.01 mg or 0.05 mg cetuximab,
there was selective distribution closer to blood vessels,
and no penetration to hypoxic regions (shown in green),
but at 24 h after injection of 1.0 mg cetuximab, the distri-
bution was more uniform within the tumor, although
there remained minimal drug penetration to hypoxic
regions identified by uptake of EF5. Staining was honey-
comb in appearance, consistent with antibody binding to
receptors on the outer membranes of tumor cells. There
Figure 1 Immmunohistochemical staining of sections of xeno-
grafts. Immmunohistochemical staining after ex vivo application of 
cetuximab to identify ErbB1 expression (upper panels) or of trastuzum-
ab to identify ErbB2 expression (lower panels). Scale bar = 100 μm.
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Figure 2 Dose response distribution of cetuximab in relation to blood vessels and regions of hypoxia in A431 xenografts. Left panels show 
the distribution of cetuximab (blue) in relation to blood vessels (red) and regions of hypoxia (green) in A431 xenografts at 24 h after an i.p. injection 
of (A) 0.01 mg, (B) 0.05 mg, and (C) 1.0 mg. In right panels staining intensity (mean +/- SEM) due to cetuximab is plotted against distance from the 
nearest blood vessel in the tumor section. Note minimal drug binding in hypoxic regions. Scale bar = 100 μm.
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was an apparent increase in intensity at very short dis-
tances from the centers of blood vessels, likely because of
lack of expression of ErbB1 on endothelial cells and peri-
cytes.
The time-dependent distribution of cetuximab after an
i.p. injection of 1.0 mg into mice bearing A431 xenografts
is shown in Fig 3. With exclusion of the immediate
perivascular region, there was a gradient of decreasing
concentration at increasing distances from blood vessels
at 30 min and 4 h after injection (Fig 3), but at 24 h and 48
h the intensity of cetuximab staining was relatively uni-
form within the tumor tissue (Figs. 2 and 3). There was
no staining due to cetuximab in hypoxic regions shown in
green. Cetuximab distribution in relation to hypoxic
regions is also plotted in Fig 3, which shows that staining
intensity due to cetuximab increases as the distance from
the hypoxic regions increases. The slopes of the relation-
ships between staining intensity of cetuximab and dis-
tance from blood vessels after various doses and times are
summarized in Table 1. These data confirm relatively uni-
form distribution at 24 h - 48 h after injection of the
higher dose of 1 mg cetuximab, with the caveat that there
is still minimal binding within hypoxic regions of the
tumors.
The distribution of cetuximab 24 h after an intravenous
injection of different doses was also investigated in A431
xenografts (data not shown). There were no significant
differences in the distributions of cetuximab after i.p. and
i.v. injection.
Time- and dose-dependent distribution of cetuximab in
MDA-MB-231 xenografts (which express intermediate
levels of ErbB1) is summarized in Table 1: with exclusion
of the immediate perivascular region, staining intensity
was relatively constant with increasing distance from the
blood vessel at most times and doses, suggesting more
rapid distribution than in the A431 tumors, which have
higher levels of expression of ErbB1. Absolute levels of
bound cetuximab increased with both dose injected and
time after injection.
Time- and dose-dependent distribution of trastuzumab
The distribution of trastuzumab at 2 h after i.v. injection
of doses of 0.1 mg, 0.3 mg or 1.0 mg into mice bearing
231-H2N xenografts (which over-express ErbB2) is
shown in Fig 4. There was selective localization close to
blood vessels at lower doses and uniform distribution
after the 1.0 mg dose. Staining due to trastuzumab was
not found in regions of hypoxia (shown in green). Stain-
ing intensities at ~20 μm from blood vessels varied by a
factor of ~1.5 after i.v. injection of doses of 0.1 mg - 1.0
mg (Table 1), suggesting that binding to proximal cells is
close to saturated.
The distribution of trastuzumab as a function of time
after injection of 0.3 mg is shown in Fig 5: There was
selective perivascular localization of trastuzumab at 30
min and 4 h after injection, but more uniform distribu-
tion after 24 h. Staining intensities at ~20 μm from blood
vessels after an injection of 0.3 mg of trastuzumab varied
only by a factor of ~1.5 at 30 min to 24 h after injection,
again suggesting early saturation of cells proximal to
blood vessels. Trastuzumab distribution in relation to
hypoxic regions is plotted in green in Fig 5, staining
intensity due to trastuzumab increases in regions close to
hypoxia as the time interval increases.
Trastuzumab was not found bound to cells of MDA-
MB-231 xenografts which express low levels of ErbB2.
Discussion
Cetuximab and trastuzumab have shown limited efficacy
in causing remission in a proportion of patients with met-
astatic colorectal cancer and breast cancer respectively
[21,22], while trastuzumab has improved survival of
women with ErbB2 positive breast cancer when given as
adjuvant therapy after chemotherapy [32-34]. Monoclo-
nal antibodies are large molecules, which are "consumed"
by binding to receptors on the cell surface, conditions
that might lead to poor penetration of tissue within solid
tumors [28]. Indeed, an early study of the distribution of a
radiolabeled monoclonal antibody into multicellular
spheroids suggested very slow penetration of tissue, with
establishment of a steep concentration gradient [35], and
more recent studies of the penetration of drugs such as
doxorubicin (which binds avidly to DNA) have shown
quite poor distribution [23-25]. Thus limited distribution
of therapeutic agents within solid tumors is a potentially
important and relatively neglected cause of drug resis-
tance, especially in the metastatic setting. Here we have
used quantitative immunohistochemistry to study the
distribution within human tumor xenografts of two ther-
apeutic monoclonal antibodies in clinical use, cetuximab
and trastuzumab, to determine if their efficacy might be
limited by failure to reach all of the target tumor cells in
an effective concentration.
The results of our study show that distribution of both
of these therapeutic antibodies is time and dose-depen-
dent. At short intervals after injection of all doses there is
a concentration gradient of staining intensity of the anti-
bodies with increasing distance from blood vessels within
tumors that strongly express the target receptor. However
there is a greater change in the gradient of cetuximab
intensity in A431 xenografts than of trastuzumab inten-
sity in 231-H2N xenografts. At moderate and high doses
the distribution then becomes more uniform with time,
while at lower doses the heterogeneous distribution is
retained. Distribution of cetuximab and trastuzumab in
relation to hypoxic regions provides a better understand-
ing of the distribution of the antibodies distal to blood
vessels. There remains minimal drug distribution toLee and Tannock BMC Cancer 2010, 10:255
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hypoxic tumor cells under all conditions, which is proba-
bly due both to limited availability of drug in these
regions, and to decreased expression of the ErbB recep-
tors under hypoxic conditions.
The difference in time dependence of the distributions
of the monoclonal antibodies as compared to that for
doxorubicin, which is relatively independent of time after
injection [24] is most likely due to the half-lives of the
drugs in the circulation: doxorubicin has a short initial
half-life [36], such that most penetration from vessels
takes place quickly, whereas monoclonal antibodies have
a half-life of days [37-39], allowing for a more constant
process of tissue penetration.
The gradients of cetuximab intensity in MDA-MB-231
xenografts, which express intermediate levels of ErbB1,
are less steep than in A431 xenografts, which express
higher levels of ErbB1, and homogeneity of distribution
of cetuximab in MDA-MB-231 xenografts was achieved
more rapidly . This is probably due to the low receptor
binding of cetuximab (i.e. less consumption of drug) by
proximal cells in MDA-MB-231 xenografts. Trastuzumab
was not identified after injection in MDA-MB-231 xeno-
grafts, which express low levels of ErbB2.
Multiple phase I and II clinical trials have established
that standard weekly dosing of cetuximab or trastuzumab
in humans achieves trough serum concentrations that are
usually above 50 μg/ml [37,38,40-42]. We did not mea-
sure serum concentration of cetuximab or trastuzumab in
our mice. Others have reported maximum serum levels of
cetuximab of ~65 μg/ml and ~400 μg/ml cetuximab after
injection of doses of 0.25 mg and 1.0 mg into mice respec-
tively [28,39], similar to those reported in patients. Injec-
Table 1: Cetuximab and trastuzumab staining intensity in different xenografts.
Cell line Monoclonal 
antibody
Dose (mg) Time after 
injection
Staining Intensity at 
20 μm from blood 
vessels (mean IU) ± SEM
Staining Intensity at 100 
μm from blood vessels 
(mean IU) ± SEM
Gradient of 
Staining 
Intensity (IU/μm)
A431 Cetuximab 0.01 24 h 26.8 ± 2.0 12.7 ± 1.4 -0.18
0.05 24 h 34.3 ± 4.8 24.5 ± 0.4 -0.12
1.0 30 min 36.1 ± 0.2 21.2 ± 1.3 -0.19
1.0 4 h 34.9 ± 2.7 25.0 ± 2.3 -0.12
1.0 24 h 35.9 ± 3.5 34.7 ± 3.9 -0.02
1.0 48 h 36.1 ± 1.2 37.8 ± 1.8 -0.02
MDA-MB-231 Cetuximab 0.01 24 h 7.0 ± 0.6 7.4 ± 1.1 0.01
0.05 24 h 7.6 ± 0.8 6.9 ± 0.9 -0.01
0.1 24 h 15.0 ± 2.8 18.5 ± 2.8 0.04
0.5 15 min 6.9 ± 1.5 6.3 ± 0.7 -0.01
0.5 30 min 8.3 ± 5.7 5.7 ± 3.7 -0.03
0.5 1 h 18.9 ± 1.1 17.0 ± 1.1 -0.02
0.5 2 h 19.1 ± 3.9 14.0 ± 2.9 -0.06
0.5 4 h 20.8 ± 1.5 24.3 ± 1.5 0.04
0.5 6 h 17.6 ± 4.0 20.3 ± 4.6 0.03
0.5 24 h 16.7 ± 2.2 20.7 ± 1.6 0.05
1.0 24 h 17.3 ± 2.7 21.2 ± 2.5 0.05
231-H2N Trastuzumab 0.1 2 h 16.8 ± 2.1 12.7 ± 1.8 -0.05
0.3 30 min 19.4 ± 0.9 16.6 ± 1.3 -0.04
0.3 2 h 23.0 ± 1.6 19.9 ± 2.1 -0.04
0.3 4 h 24.0 ± 2.1 18.5 ± 3.0 -0.07
0.3 24 h 29.0 ± 1.0 27.3 ± 0.8 -0.02
1.0 2 h 27.0 ± 1.3 26.2 ± 1.4 -0.01
Staining intensity of cetuximab and trastuzumab at 20 μm and 100 μm from blood vessels in A431, MDA-MB-231 and 231-H2N xenografts. 
Gradient of staining intensity is shown.Lee and Tannock BMC Cancer 2010, 10:255
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Figure 3 Time response distribution of cetuximab in relation to blood vessels and regions of hypoxia in A431 xenografts. Left panels show 
the distribution of cetuximab (blue) in relation to blood vessels (red) and regions of hypoxia (green) in A431 xenografts at (A) 30 min, (B) 4 h and (C) 
48 h after i.p. injection of 1.0 mg. In right panels staining intensity due to cetuximab is plotted against distance to the blood vessel in red and distance 
to region of hypoxia in green. Scale bar = 100 μm.
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Figure 4 Dose response distribution of trastuzumab in relation to blood vessels and regions of hypoxia in 231-H2N xenografts. Left panels 
show the distribution of trastuzumab (blue) in relation to blood vessels (red) and regions of hypoxia (green) in MDA-MB-231 breast cancer xenografts 
transfected with ErbB2 (231-H2N) at 2 h after i.v. injection of (A) 0.1 mg, (B) 0.3 mg and (C) 1.0 mg. In right panels staining intensity (mean +/- SEM) 
due to trastuzumab is plotted against distance from the nearest blood vessel in the tumor section. Note minimal drug binding in hypoxic regions. 
Scale bar = 100 μm.
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Figure 5 Time response distribution of trastuzumab in relation to blood vessels and regions of hypoxia in 231-H2N xenografts. Left panels 
show the distribution of trastuzumab (blue) in relation to blood vessels (red) in MDA-MB-231 breast cancer xenografts transfected with ErbB2 (231-
H2N) at (A) 30 min, (B) 4 h and (C) 24 h after i.v. injection of 0.3 mg trastuzumab. In right panels staining intensity due to trastuzumab is plotted against 
distance to the blood vessel in red and distance to region of hypoxia in green. Scale bar = 100 μm.
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tion of trastuzumab was reported to lead to serum levels
of about 5 ng/ml at 6-24 hours after i.p injection of a sin-
gle low dose of 0.3 mg/kg into mice [43]; if pharmacoki-
netics were linear this would imply doses of ~15 mg/
mouse to achieve levels of 10 ug/ml in serum, but it
seems unlikely that pharmacokinetics of the two antibod-
ies would differ by such a large amount.
Several other investigators have studied the distribu-
tion of various antibodies, or antibody fragments, in
tumors. Their results depend on changes in blood flow
[44] the affinity of the antibodies for their targets, but in
general these authors have reported problems of hetero-
geneity of distribution at various times after their admin-
istration [45-48]. We were able to identify two other
studies of the distribution of trastuzumab (but none of
cetuximab) in solid tumors. Dennis et al used intravital
microscopy to detect trastuzumab, conjugated to fluores-
cein isothiocyanate (FITC), in relation to blood vessels of
MMTV/HER2 transgenic mice (expressing high levels of
ErbB2) that were constrained to grow in a transparent
window chamber; they reported perivascular localization
of trastuzumab at 24 hours after injection of 10 mg/kg
(about 0.25 mg/mouse) [49]. Their study suggests poorer
(or slower) distribution of trastuzumab than the one
reported here; a possible reason is higher expression of
ErbB2 in the MMTV/HER tumors as compared to the
231-H2N xenografts investigated in our study. Baker et al
used similar methods to our own, and investigated time-
dependent distributions of trastuzumab in xenografts
(that did or did not express ErbB2) after i.p. injection
doses in the range of 4-20 mg/kg (about 0.1- 0.5 mg/
mouse) [50]. They found perivascular distribution of
drug at 3 h, and that tumor margins reached saturation
with trastuzumab more rapidly than the (poorly-vascu-
larized) interior. Drug distribution became more uniform
at 24 h as compared to 8 h after injection of 4 mg/kg, but
some heterogeneity of trastuzumab distribution was
observed in the tumor under all conditions; this is consis-
tent with our finding of poor drug uptake in hypoxic
tumor regions.
Conclusions
Limited distribution of anticancer drugs (including
molecular targeted agents) to cells within human tumors
is an important mechanism that may lead to clinical drug
resistance. The present study suggests that while distribu-
tion of cetuximab and trastuzumab within tumor tissue is
time and dose-dependent, the sustained concentrations
a c h i e v e d  b y  r e p e a t e d  d o s i n g  i n  p a t i e n t s  i s  l i k e l y  t o
achieve relatively uniform concentration within most
areas of tumors, although there is poor drug binding in
hypoxic regions. Thus the presence of hypoxia may be
associated with resistance to these targeted agents, as
well as to radiotherapy and chemotherapy.
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